Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Oryx to market Angiomax in Canada

Nov. 5, 2002

Positive phase I results for GH-9001

Oct. 29, 2002

New PAR-1 antagonists prepared and tested at Ortho-McNeil

Oct. 29, 2002

Baxter submits MAA in E.U. for rAHF-PFM

Oct. 25, 2002

New factor Xa inhibitors in early development at Morphochem

Oct. 24, 2002

New factor VIIa inhibitors in early development at Chugai

Oct. 23, 2002

Bayer researchers describe novel factor Xa inhibitors

Oct. 21, 2002

Merck scientists present two series of thrombin inhibitors

Oct. 16, 2002

New factor Xa inhibitors in development at Lilly

Oct. 15, 2002

Angiomax receives clearance in Canada

Oct. 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...